Paige.AI has received breakthrough device designation from the US Food and Drug Administration (FDA) for a cancer diagnosis solution based on artificial intelligence (AI).

The company’s pathology tools build on technology developed by co-founder Thomas Fuchs and are developed under a licensing agreement with the Memorial Sloan Kettering Cancer Center (MSK).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the agreement, Paige.AI receives de-identified images of more than one million pathology slides. MSK has been digitising the slides for four years and is now processing another four million.

“Paige.AI is focused on providing AI tools to pathologists that will enable them to become faster and more accurate in their diagnosis.”

This dataset is being used to create a comprehensive portfolio of AI products across cancer subtypes to support pathologists worldwide.

Paige.AI CEO Leo Grady said: “Paige.AI is focused on providing AI tools to pathologists that will enable them to become faster and more accurate in their diagnosis and treatment recommendations for the care of cancer patients.

“We are thrilled to receive breakthrough designation and look forward to collaborating with the FDA to bring our products to market, starting with prostate cancer and expanding from there.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The FDA grants breakthrough device status to technologies that have the potential to facilitate more effective diagnosis or treatment for life-threatening or debilitating diseases. The designation helps accelerate product development will offer priority regulatory review for Paige.AI’s pathology solution.

Fuchs added: “We are honoured to have been granted breakthrough designation by the FDA, which underscores the groundbreaking nature of our technology as the leading clinical-grade AI in computational pathology to combine vast amounts of high-quality data with unique deep learning architectures in service of delivering better patient care.”